Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Neuro-oncology - 1 Oct 2016

Garber Sarah T, Hashimoto Yuuri, Weathers Shiao-Pei, Xiu Joanne, Gatalica Zoran, Verhaak Roel G W, Zhou Shouhao, Fuller Gregory N, Khasraw Mustafa, de Groot John, Reddy Sandeep K, Spetzler David, Heimberger Amy B

Abstract excerpt

BACKGROUND: Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic and epigenetic alterations are undefined but nonetheless highly relevant to combinatorial treatments. METHODS: Patients with CNS malignancies were profiled by Caris Life Sciences from 2009 to 2016. Immunohistochemistry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to High-Throughput Nucleotide Sequencing

Share to Immunohistochemistry

Share to In Situ Hybridization, Fluorescence

Share to Lymphocytes, Tumor-Infiltrating

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 27370400
DOI: 10.1093/neuonc/now132
PMCID: PMC5035527

Genes

PTEN
IDH1
MGMT
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.PMID 27370400Read ↗

Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas.Semantic proximity Read ↗

Immunogenetics of glioblastoma: the future of personalized patient managementSemantic proximity Read ↗

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read ↗

A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas DatasetSemantic proximity Read ↗

Molecular and Clinical Determinants of Response to Immunotherapy in High-Grade GliomaSemantic proximity Read ↗

Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort StudySemantic proximity Read ↗

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed GlioblastomaSemantic proximity Read ↗

Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis.Semantic proximity Read ↗

Glioma targeted therapy: insight into future of molecular approaches.Semantic proximity Read ↗

Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic playersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.